Jane Street’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $238K | Sell |
3,500
-1,300
| -27% | -$92.1K | ﹤0.01% | 9733 |
|
|
2025
Q4 | $365K | Sell |
4,800
-197,000
| -98% | -$14.3M | ﹤0.01% | 8399 |
|
|
2025
Q3 | $12.4M | Buy |
201,800
+195,100
| +2,912% | +$10.2M | ﹤0.01% | 2153 |
|
|
2025
Q2 | $327K | Sell |
6,700
-700
| -9% | -$33.2K | ﹤0.01% | 7704 |
|
|
2025
Q1 | $377K | Sell |
7,400
-23,500
| -76% | -$1.17M | ﹤0.01% | 7402 |
|
|
2024
Q4 | $1.39M | Buy |
30,900
+19,300
| +166% | +$826K | ﹤0.01% | 4791 |
|
|
2024
Q3 | $430K | Sell |
11,600
-26,300
| -69% | -$880K | ﹤0.01% | 7456 |
|
|
2024
Q2 | $1.16M | Buy |
+37,900
| New | +$1.23M | ﹤0.01% | 5499 |
|
|
2024
Q1 | – | Sell |
-25,400
| Closed | -$700K | – | 9902 |
|
|
2023
Q4 | $700K | Sell |
25,400
-30,600
| -55% | -$700K | ﹤0.01% | 6193 |
|
|
2023
Q3 | $1.25M | Buy |
56,000
+1,800
| +3% | +$66.9K | ﹤0.01% | 4823 |
|
|
2023
Q2 | $2.2M | Sell |
54,200
-12,700
| -19% | -$621K | ﹤0.01% | 4020 |
|
|
2023
Q1 | $3.24M | Buy |
66,900
+53,200
| +388% | +$2.43M | ﹤0.01% | 3036 |
|
|
2022
Q4 | $523K | Buy |
13,700
+4,900
| +56% | +$204K | ﹤0.01% | 6050 |
|
|
2022
Q3 | $442K | Buy |
8,800
+400
| +5% | +$19.6K | ﹤0.01% | 6906 |
|
|
2022
Q2 | $337K | Buy |
8,400
+1,300
| +18% | +$45.6K | ﹤0.01% | 7416 |
|
|
2022
Q1 | $265K | Buy |
+7,100
| New | +$274K | ﹤0.01% | 8588 |
|
|
2021
Q3 | – | Sell |
-9,200
| Closed | -$389K | – | 10563 |
|
|
2021
Q2 | $389K | Sell |
9,200
-1,800
| -16% | -$77.1K | ﹤0.01% | 7712 |
|
|
2021
Q1 | $521K | Sell |
11,000
-1,300
| -11% | -$77.2K | ﹤0.01% | 6728 |
|
|
2020
Q4 | $751K | Sell |
12,300
-22,300
| -64% | -$1.31M | ﹤0.01% | 5120 |
|
|
2020
Q3 | $1.62M | Buy |
34,600
+20,900
| +153% | +$1.03M | ﹤0.01% | 3356 |
|
|
2020
Q2 | $695K | Buy |
+13,700
| New | +$673K | ﹤0.01% | 4586 |
|
|
2019
Q4 | – | Sell |
-18,100
| Closed | -$612K | – | 5602 |
|
|
2019
Q3 | $612K | Buy |
+18,100
| New | +$788K | ﹤0.01% | 3279 |
|
|
2018
Q4 | – | Sell |
-5,000
| Closed | -$235K | – | 5539 |
|
|
2018
Q3 | $235K | Buy |
+5,000
| New | +$207K | ﹤0.01% | 4506 |
|
|
2017
Q4 | – | Sell |
-15,400
| Closed | -$308K | – | 5059 |
|
|
2017
Q3 | $308K | Buy |
+15,400
| New | +$302K | ﹤0.01% | 3652 |
|
|
2016
Q4 | – | Sell |
-56,200
| Closed | -$787K | – | 4495 |
|
|
2016
Q3 | $787K | Buy |
+56,200
| New | +$457K | ﹤0.01% | 2246 |
|
|
2016
Q2 | – | Sell |
-22,800
| Closed | -$147K | – | 4481 |
|
|
2016
Q1 | $147K | Buy |
+22,800
| New | +$396K | ﹤0.01% | 3803 |
|
|
2015
Q4 | – | Sell |
-123,500
| Closed | -$3.3M | – | 4358 |
|
|
2015
Q3 | $3.3M | Buy |
+123,500
| New | +$5.28M | 0.02% | 642 |
|
Other funds holding PTCT
RI
VPM
VCM
AC
Jane Street's PTCT Position: Q1 2026 in Review
Jane Street sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 3,925 shares — an estimated $278K sold.
Jane Street first reported a position in PTCT in Q2 2014 and held it in 35 quarters. The position peaked at $22.5M in Q4 2023. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Jane Street reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 3,925 PTC Therapeutics shares in Q1 2026, an estimated $278K.
- Jane Street first reported a position in PTC Therapeutics in Q2 2014 and held it in 35 quarters.
- Jane Street's PTC Therapeutics position peaked at $22.5M in Q4 2023.
- 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.